Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety

Detalhes bibliográficos
Autor(a) principal: Oliveira, I. R. de
Data de Publicação: 1996
Outros Autores: Sena, E. P. de, Pereira, E. L. A., Ribeiro, M. G., Silva, E. de Castro e, Bacaltchuk, J.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://www.repositorio.ufba.br/ri/handle/ri/8443
Resumo: Texto completo: acesso restrito. p.349–358
id UFBA-2_3fa1cec2dcee3186d4bb769dd5e15e09
oai_identifier_str oai:repositorio.ufba.br:ri/8443
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Oliveira, I. R. deSena, E. P. dePereira, E. L. A.Ribeiro, M. G.Silva, E. de Castro eBacaltchuk, J.Oliveira, I. R. deSena, E. P. dePereira, E. L. A.Ribeiro, M. G.Silva, E. de Castro eBacaltchuk, J.2013-02-15T13:34:30Z19960269-4727http://www.repositorio.ufba.br/ri/handle/ri/8443v. 21, n. 6Texto completo: acesso restrito. p.349–358The aim of this study was to compare the shortterm clinical efficacy and safety of risperidone with haloperidol and placebo. A meta-analysis of seven published randomized double-blind controlled trials was carried out. Study quality was assessed. The proportion of patients failing to reach at least 20% improvement on the positive and negative syndrome scale (PANSS) or brief psychiatric rating scale (BPRS), the proportion of patients discontinuing treatment because of adverse effects and the number of patients who needed antiparkinsonian medication were abstracted for use as outcome measures. Treatment failure was present in 50% of risperidone-treated patients compared to 66% in those treated with haloperidol and 83% in those treated with placebo. It would be necessary to treat 11 patients with risperidone to prevent one treatment failure in those patients treated with haloperidol (Odds ratio (OR) = 0.74, 95% CI of 0.58-0.94, P=0.02). Pooling of the three multicentre trials which included placebo as a treatment arm, showed that one in three patients treated with risperidone 4–16 mg/day (OR=0.22, 95% CI of 0.13-0.39, P<0.00001) and one in six treated with haloperidol 10–20 mg/day (OR=0.44, 95% CI of 0.22-0.84, P=0.02) would derive significant benefit. Moreover, there was a highly significant greater need for anticholinergic medication due to extrapyramidal symptoms (EPS) in the haloperidol-treated patients compared to risperidone (OR=0.54, 95% CI of 0.42-0.70, P<0.00001). In conclusion, risperidone seems to be more effective and causes less EPS than haloperidol, as suggested by the significantly lower requirement for antiparkinsonian medication.Submitted by Suelen Reis (suelen_suzane@hotmail.com) on 2013-02-15T13:34:30Z No. of bitstreams: 1 Oliveira.pdf: 676740 bytes, checksum: e1efd988cd93ba3019059670423693eb (MD5)Made available in DSpace on 2013-02-15T13:34:30Z (GMT). No. of bitstreams: 1 Oliveira.pdf: 676740 bytes, checksum: e1efd988cd93ba3019059670423693eb (MD5) Previous issue date: 1996http://dx.doi.org/10.1111/j.1365-2710.1996.tb00030.xreponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBARisperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safetyJournal of Clinical Pharmacy and Therapeuticsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article10000-01-01enginfo:eu-repo/semantics/openAccessORIGINALOliveira.pdfOliveira.pdfapplication/pdf676740https://repositorio.ufba.br/bitstream/ri/8443/1/Oliveira.pdfe1efd988cd93ba3019059670423693ebMD51LICENSElicense.txtlicense.txttext/plain1762https://repositorio.ufba.br/bitstream/ri/8443/2/license.txt1b89a9a0548218172d7c829f87a0eab9MD52TEXTOliveira.pdf.txtOliveira.pdf.txtExtracted texttext/plain30785https://repositorio.ufba.br/bitstream/ri/8443/3/Oliveira.pdf.txtf1dbf4088e320c347a402f52b3f38539MD53ri/84432022-07-05 14:03:02.196oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:03:02Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety
dc.title.alternative.pt_BR.fl_str_mv Journal of Clinical Pharmacy and Therapeutics
title Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety
spellingShingle Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety
Oliveira, I. R. de
title_short Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety
title_full Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety
title_fullStr Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety
title_full_unstemmed Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety
title_sort Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety
author Oliveira, I. R. de
author_facet Oliveira, I. R. de
Sena, E. P. de
Pereira, E. L. A.
Ribeiro, M. G.
Silva, E. de Castro e
Bacaltchuk, J.
author_role author
author2 Sena, E. P. de
Pereira, E. L. A.
Ribeiro, M. G.
Silva, E. de Castro e
Bacaltchuk, J.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Oliveira, I. R. de
Sena, E. P. de
Pereira, E. L. A.
Ribeiro, M. G.
Silva, E. de Castro e
Bacaltchuk, J.
Oliveira, I. R. de
Sena, E. P. de
Pereira, E. L. A.
Ribeiro, M. G.
Silva, E. de Castro e
Bacaltchuk, J.
description Texto completo: acesso restrito. p.349–358
publishDate 1996
dc.date.issued.fl_str_mv 1996
dc.date.accessioned.fl_str_mv 2013-02-15T13:34:30Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.repositorio.ufba.br/ri/handle/ri/8443
dc.identifier.issn.none.fl_str_mv 0269-4727
dc.identifier.number.pt_BR.fl_str_mv v. 21, n. 6
identifier_str_mv 0269-4727
v. 21, n. 6
url http://www.repositorio.ufba.br/ri/handle/ri/8443
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.pt_BR.fl_str_mv http://dx.doi.org/10.1111/j.1365-2710.1996.tb00030.x
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/8443/1/Oliveira.pdf
https://repositorio.ufba.br/bitstream/ri/8443/2/license.txt
https://repositorio.ufba.br/bitstream/ri/8443/3/Oliveira.pdf.txt
bitstream.checksum.fl_str_mv e1efd988cd93ba3019059670423693eb
1b89a9a0548218172d7c829f87a0eab9
f1dbf4088e320c347a402f52b3f38539
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1793970085154521088

Registros relacionados